Evidence map›Paper›PMID 28881381›Full record

ArticleCancer2017

Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study.

Elizabeth M Cespedes Feliciano, Valerie S Lee, Carla M Prado, Jeffrey A Meyerhardt, Stacey Alexeeff, Candyce H Kroenke, Jingjie Xiao, Adrienne L Castillo, Bette J Caan

2 registry-linked trialsAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 60 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 3 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07255001 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

Monitoring Physical Function Changes in Patients With Pancreatic Ductal Adenocarcinoma: Potential for Better Understanding of Treatment Trajectory and Survival

TypeinterventionalSponsorBritish Columbia Cancer AgencyRan2025 to 2027Enrolled50ConditionsPancreatic Ductal Adenocarcinoma (PDAC), Hand Grip StrengthArmsHand grip strength assessments using a dynamometer
NCT07624370 enrolling by invitationnot on this mapstarted 2025, after this paper: background citation

Impatto Della Diagnosi di fragilità Sulla tossicità da Terapia in Pazienti Anziani Affetti da Tumore oncoLogIco e onCoEmatologico.

TypeobservationalSponsorAzienda Socio Sanitaria Territoriale Ovest Milanese, Ospedale di LegnanoRan2025 to 2028Enrolled160ConditionsSarcopenia in Elderly, Frailty/Sarcopenia, Oncological Patients, Hematologic DiseaseArmsFrailty evaluation
3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 3 syntheses or guidelines pooled it, 113 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. A pragmatic, single-arm clinical trial of a dose modification algorithm for preventing cytopenia-related delays during FOLFOX chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Improving the prediction of chemotherapy dose-limiting toxicity in colon cancer patients using an AI-CT-based 3D body composition of the entire L1-L5 lumbar spine.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Elizabeth M Cespedes FelicianoDivision of Research, Kaiser Permanente Northern California, Oakland, California.ORCID http://orcid.org/0000-0003-1192-4017
Valerie S LeeDivision of Research, Kaiser Permanente Northern California, Oakland, California.
Carla M PradoDepartment of Agricultural, Food and Nutritional Sciences, University of Alberta, Edmonton, Alberta, Canada.
Jeffrey A MeyerhardtDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Stacey AlexeeffDivision of Research, Kaiser Permanente Northern California, Oakland, California.
Candyce H KroenkeDivision of Research, Kaiser Permanente Northern California, Oakland, California.
Jingjie XiaoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Adrienne L CastilloDivision of Research, Kaiser Permanente Northern California, Oakland, California.
Bette J CaanDivision of Research, Kaiser Permanente Northern California, Oakland, California.
Kaiser Permanente · USHarvard University · USUniversity of Alberta · CA

Funding

Dietary And Lifestyle Determinants Of Colon Cancer Recurrence and SurvivalR01CA118553 · NCI · YALE UNIVERSITY · PI FUCHS, CHARLES S · 2007 to 2019
$4.4M
Body Composition, Weight, and Colon Cancer SurvivalR01CA175011 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI CAAN, BETTE J · 2013 to 2017
$3.1M
NCI NIH HHS R01 CA118553NCI NIH HHS R01 CA175011
6 · The paper itself

Abstract

backgroundFor many chemotherapy regimens dosed based on body surface area (BSA), patients experience dose reductions or delays or discontinue treatment, thereby reducing survival. Consideration of body composition may be useful in individualizing chemotherapy dosing, but to the authors' knowledge few studies to date have examined the association of body composition with chemotherapy tolerance in patients with colon cancer.

methodsThe authors identified patients with nonmetastatic colon cancer who were diagnosed from 2006 through 2011 at Kaiser Permanente and who received leucovorin calcium/calcium folinate, 5-fluorouracil, and oxaliplatin (FOLFOX) as initial adjuvant chemotherapy (533 patients). Patients' muscle mass was quantified using clinically acquired computed tomography scans. The authors quantified chemotherapy doses, treatment dates, and related toxicities using the electronic medical record. In logistic regression models adjusting for age, sex, and American Joint Committee on Cancer stage of disease, the authors examined associations of muscle tertiles with early treatment discontinuation (<6 cycles), treatment delay (>3 days off schedule for ≥3 times), and/or dose reduction (relative dose intensity ≤ 0.70, based on planned treatment).

resultsThe average age of the patients at the time of diagnosis was 58.7 years; BSA was 1.9 m

conclusionsLower muscle mass is associated with greater toxicity and poor chemotherapy adherence among patients receiving FOLFOX. Many chemotherapy drugs are dosed based on BSA, but treatment may be better individualized if muscle mass is considered. Cancer 2017;123:4868-77. © 2017 American Cancer Society.

Indexed as

Body Mass IndexAdultAgedAnalysis of VarianceAntineoplastic Combined Chemotherapy ProtocolsBody CompositionChemotherapy, AdjuvantChi-Square DistributionColectomyColonic NeoplasmsDatabases, FactualDose-Response Relationship, DrugDrug Administration ScheduleFemaleFluorouracilHumansFluorouracilLeucovorinOrganoplatinum Compoundsbody compositionbody surface areachemotherapycolon cancerdose-limiting toxicityrelative dose intensityskeletal muscle mass

Identifiers

PMID28881381
PMCPMC5716836
OpenAlexW2751704934

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.